leniolisib

Ligand id: 9424

Name: leniolisib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 83.48
Molecular weight 450.2
XLogP 2.28
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one
International Nonproprietary Names
INN number INN
10255 leniolisib
Synonyms
CDZ-173 | CDZ173 | Example 67 [WO2012004299]
Database Links
CAS Registry No. 1354690-24-6 (source: WHO INN record)
ChEMBL Ligand CHEMBL3643413
PubChem CID 57495353
Search Google for chemical match using the InChIKey MWKYMZXCGYXLPL-ZDUSSCGKSA-N
Search Google for chemicals with the same backbone MWKYMZXCGYXLPL
Search PubMed clinical trials leniolisib
Search PubMed titles leniolisib
Search PubMed titles/abstracts leniolisib
Search UniChem for chemical match using the InChIKey MWKYMZXCGYXLPL-ZDUSSCGKSA-N
Search UniChem for chemicals with the same backbone MWKYMZXCGYXLPL
Comments
Leniolisib is an orally active, potent phosphatidylinositol 3-kinase inhibitor (PI3K) inhibitor, with selectivity for the PI3Kδ isoform. Novartis originally developed CDZ173 as a treatment for autoimmune diseases, but has rapidly repurposed it for its potential in patients with Activated PI3K Delta Syndrome (APDS, a.k.a. p110 delta activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency, or PASLI). APDS is a rare genetic immunodeficiency disease characterised by lymphoproliferation, recurrent infections from childhood, and an increased risk of EBV-associated lymphoma. APDS is known to be caused by autosomal dominant, gain-of-function mutations in the PIK3CD gene which encodes the PI3Kδ protein [2-3].